ACE2 and COVID-19: Since ACE2 inhibitors and Ang II AT1 receptor antagonists have the potential to increase ACE2 expression, which may aggravate COVID-19, we recommend critical publications regarding the use of renin-angiotensin inhibitors and COVID-19 (Bavishi et al., 2020; Peiró and Moncada, 2020; Sanchis-Gomar et al., 2020; Sommerstein et al., 2020; Vaduganathaan et al., 2020).